Hematology Transfusion and Cell Therapy Journal Citation Rate 2026
2531-1379
eISSN 2531-1387
Elsevier BV
BR
Q4 Quartile Open Access
About Hematology Transfusion and Cell Therapy
Hematology Transfusion and Cell Therapy (HTCT) is a peer-reviewed academic journal, published by Elsevier BV in BR, catalogued under ISSN 2531-1379 (e-ISSN 2531-1387). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 0.08 (Q4 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It is fully open access.
Hematology Transfusion and Cell Therapy Citation Rate 2026 — In Context
Hematology Transfusion and Cell Therapy has a 2025 2-Year Citation Rate (OpenAlex) of 0.08, placing it in the Q4 quartile. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
As a fully open-access publication, Hematology Transfusion and Cell Therapy makes all articles freely available to readers.
Researchers looking to publish in Hematology Transfusion and Cell Therapy should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Hematology Transfusion and Cell Therapy against similar journals in the field, use our journal comparison tool.
| ISSN (Print) | 2531-1379 |
|---|---|
| ISSN (Online) | 2531-1387 |
| Publisher | Elsevier BV |
| Country | Brazil |
| APC / Cost | Inquire with Publisher |
In-depth profile & metrics
Hematology Transfusion and Cell Therapy is published by Elsevier BV and based in Brazil. It publishes on an open-access basis.
Hematology Transfusion and Cell Therapy is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
Its most recent citation rate stands at 0.084.
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Hematology Transfusion and Cell Therapy
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 0.084 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Research Highlights
Recently published high-impact papers in this journal:
-
Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?
Musab M. A. Omar, Majed A Alanazi, Denise E. Jackson • 2026
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S2898598332
Get weekly updates
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.